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Abstract: Chronic neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease
(PD), and prion diseases are characterised by the accumulation of abnormal conformers of a host
encoded protein in the central nervous system. The process leading to neurodegeneration is still
poorly defined and thus development of early intervention strategies is challenging. Unique amongst
these diseases are Transmissible Spongiform Encephalopathies (TSEs) or prion diseases, which have
the ability to transmit between individuals. The infectious nature of these diseases has permitted
in vivo and in vitro modelling of the time course of the disease process in a highly reproducible manner,
thus early events can be defined. Recent evidence has demonstrated that the cell-to-cell spread of
protein aggregates by a “prion-like mechanism” is common among the protein misfolding diseases.
Thus, the TSE models may provide insights into disease mechanisms and testable hypotheses for
disease intervention, applicable to a number of these chronic neurodegenerative diseases.
Keywords: neurodegeneration; prion; transmissible spongiform encephalopathies (TSE); protein
misfolding; proteinopathies
1. Introduction
Chronic neurodegenerative diseases encompass a number of protein misfolding diseases, which
can be both heritable and sporadic. These include Alzheimer’s disease (AD), Parkinson’s disease
(PD) and Transmissible Spongiform Encephalopathies (TSEs) or prion diseases. During the course of
these diseases, a host-encoded protein misfolds and accumulates in the central nervous system (CNS).
Multiple forms of misfolded proteins can be identified in the CNS ranging from small oligomeric
structures through to large amyloid deposits [1–5]. The neurotoxicity of the different forms of misfolded
proteins has been intensively debated and current literature favours the oligomeric structures as being
the more neurotoxic [6–14]. The pathogenesis of these diseases is not clear since protein deposits can
also be found in apparently healthy individuals [15]. Diagnosis of these diseases often occurs at the
latter stages when clinical signs become evident; however, therapeutic interventions have little effect
at this stage [16–18]. Moreover, the early stages of these diseases are not yet well defined and, thus,
few therapeutic targets have been identified in the pre-clinical or early clinical phases of disease.
Traditionally, TSEs have been considered distinct from the other neurodegenerative diseases
due to their infectious nature. The nature of the infectious agent has been studied for many decades
in numerous large and small animal models, leading to the “prion hypothesis”. This hypothesis
predicts that an abnormal conformer of the prion protein is able to bind to the normal conformer,
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PrPC, and induce changes in conformation resulting in an auto-catalytic reaction, which produces
abnormal isoforms of the prion protein [19]. Moreover, these abnormal conformers spread both within
an individual and between individuals. Originally, these abnormal isoforms (PrPSc) were recognised
due to their resistance to proteinase K (PK), but as detection techniques and our understanding of the
abnormal protein has increased, so has the range of abnormal isoforms, such as PK-sensitive forms
of PrPSc, oligomeric PrP, protofibrils and amyloid fibrils, etc. It is still unclear which of these specific
conformers may be associated with neurotoxicity and TSE infectivity.
This “prion-like” spread of protein within the CNS has been more recently observed in a
number of non-prion disease associated proteins such as amyloid-beta (Aβ) [20,21], tau [22–25]
and α-synuclein [26,27]. The host protein is considered critical to this cycle of formation and spread.
Transmission of a misfolded protein has also been described from one individual to another in a
number of experimental models and, more recently, in patients [28,29]. However, to date, there is no
epidemiological evidence for inter-individual transmission of diseases associated with proteins other
than PrP [30]. Such studies indicate the need to understand the role of the misfolded protein in the
infectious and neurotoxic process, in order to accurately assess the risk to individuals and populations
from the protein misfolding diseases. This review will describe the progress that has been made
using the TSE models in understanding the mechanisms of chronic neurodegeneration and the role of
misfolded protein in disease.
2. In Vitro Modelling of Protein Misfolding
The TSEs have provided us with invaluable in vitro systems to assess very small amounts of a
misfolded protein in a particular tissue or brain region. These assays have been developed as diagnostic
tools but also provide highly sensitive assay systems to probe disease mechanisms. The initial studies
demonstrated that enriched preparations of PrPSc containing brain homogenates, added to recombinant
PrP (recPrP), could induce the formation of small quantities of PrP aggregates [31]. Importantly, this
reaction occurred in purified recPrP preparations, and, therefore, demonstrated the ability of cell-free
protein-templated conversion (Figure 1). The Protein Misfolding Cyclic Amplification (PMCA) assay
was developed, which involved cycles of sonication to break down aggregates and incubation to allow
further amplification. Additionally, normal uninfected brain homogenate was used to provide PrPC
substrate rather than recPrP [32]. Using the PMCA assay, others have identified non-PrP protein
factors, which could be important in the conversion mechanism. For example, following the addition
of polyanionic compounds (e.g., RNA) to purified PrPC, in the absence of misfolded prion protein
as a seed, de novo generation of PK-resistant PrP (PrPRes) was observed [33,34]. Moreover, when
experimentally inoculated into mice, this de novo generated PrPRes initiated a prion-like disease [35].
A further study then demonstrated high levels of infectivity resulting from the amplification of recPrP
in the presence of lipids purified from murine liver [36]. However, evidence from another study using
recPrP with physico-chemical characteristics similar to those detected in PrPSc extracted from infected
animals showed no evidence of infectivity [37].
It remains unclear whether co-factors are involved in the conversion mechanism in vivo.
However, understanding that specific types of lipids could play important roles in PrP conversion
may be especially relevant when considering the cell-to-cell prion-like spread. As targeting of
misfolded proteins, to our current understanding, is highly specific and occurs in a pattern resembling
neuronal connectivity, the differences in molecular composition of neurons, specifically at the synapse,
between neuroanatomically distinct brain regions, could prove important in defining the mechanism
of protein-templated conversion.
These assay systems have now been extended beyond the measurement of PrPSc into other
misfolded proteins such as α-synuclein and Aβ [38,39]. Roostaee et al. [38] showed that a modified
PMCA protocol could be used to amplify α-synuclein. The use of PMCA suggests that, as
with PrP, interaction between aggregates of pathological α-synuclein and soluble α-synuclein is
sufficient to initiate or seed formation of α-synuclein and is thus evidence for self-propagation [38].
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Furthermore, PMCA has been adapted for the detection of Aβ oligomers, with initial studies
demonstrating that it can distinguish between AD and non-AD patients with a specificity of 90%
using cerebrospinal fluid [39]. Current research trends across many neurodegenerative diseases
attempt to define spread of misfolded proteins using relatively insensitive detection methods, such
as immunohistochemistry or silver staining (reviewed by [40]). In light of the development of these
assays to study prion-conversion and the increasing understanding that such assays can be utilised for
detection of α-synuclein or Aβ, cell-free conversion assays have the potential to gain further insight
into the role of the misfolded proteins in neurodegeneration.
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added to the reaction in the first instance. 
3. In Vivo TSE Models of Chronic Neurodegeneration 
When animals are experimentally infected with a TSE, this represents the “start-point” of the 
disease process. Well defined time course studies can then be conducted to investigate the disease 
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Figure 1. Diagrammatic representation of cell-free conversion assays. A small quantity of a
brain homogenate containing PrPSc, usually at quantities lower than is normally detectable when
immunoblotting, is added to a pool of “normally” folded host-encoded protein. This can be either
purified recombinant proteins (recPrP) or an uninfected brain homogenate. Briefly, the assays undergo
periods of incubation, whereby the PrPSc seeds can interact with recPrP and cause protein misfolding
and aggregation. Intermittently, periods of sonication are used to break down larger aggregates to
allow further conversion of recPrP to PrPSc. The assay products are then assessed using Western blot
analysis. These systems result in a large accumulation of PrPSc, which have occurred in a cell-free
system, and, as the result of protein-templated conversion directed from the initial extremely small
quantity of PrPSc added to the reaction in the first instance.
3. In Vivo TSE Models of Chronic Neurodegeneration
When animals are xp rimentally infected with a TSE, this represents the “star -point” of the
disease process. Well d fi ed time co rse studies can then be conducted to investigate the disease
process from the disease initiation through preclinical and clinical phases of disease [41]. An extensive
number of transgenic models have been produced with alterations in the prion protein gene including
point and insertional mutations, alterations in the glycosylation status of PrP and alterations in the
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species from which the PrP is derived. These models range from the gene targeted knock-in models
to standard microinjection models overexpressing PrP at various different levels, allowing extensive
studies of disease transmission both within and between species [42–45].
PrPC has been demonstrated to be an absolute requirement for disease since, in its absence, mice
are resistant to TSEs [46,47] although infection can persist in the PrP knockout (PrP´{´) mice for up to
600 days (Manson, personal communication). PrP´{´ mice which have wild type (PrP+/+) tissue grafts
into the brain have demonstrated TSE specific histopathologic alterations of PrP+/+ graft tissue but
preservation of host PrP´{´ neurons when experimentally infected with a TSE [48]. This observation
demonstrates that accumulation of PrPSc is not neurotoxic in the absence of endogenous PrPC.
Models in which the sequence of the host PrP gene has been altered have also demonstrated the
importance of host sequence in determining the incubation time and pathological lesions in the disease
process [49–55]. Moreover, the glycosylation status of host PrP has been shown to have a remarkable
influence on susceptibility and resistance of the host to disease [56–59].
4. Time Course Studies of TSE
Understanding the pathophysiological progression of chronic neurodegenerative diseases is of
importance in determining how an abnormally folded protein may cause disease. Although incubation
periods and the timing of events may vary between TSE models, the models themselves
recapitulate pathologies observed in natural diseases such as spongiform degeneration of the brain,
neuronal loss, abnormal protein deposition, synaptic degeneration and gliosis (reviewed in [60,61]).
Behavioural deficits can be observed throughout the incubation period and correlated to pathogenesis
of the CNS, and, eventually, overt clinical symptoms of disease are observed.
Following inoculation with a TSE agent, small accumulations of PrPSc can be initially detected in
restricted regions of the brain, shortly followed or concurrently with glial cell responses (microglia
and/or astrocytes), often within the same brain regions. This is followed by synaptic protein loss and
electrophysiological deficits. It is around this time that early behavioural deficits may be observed
i.e., changes in burrowing behaviour and glucose consumption [62–66]. Indeed, the behavioural
deficits can be correlated to synaptic loss in specific brain regions such as the hippocampus and
hypothalamus [67,68]. Throughout the time course of disease, behavioural changes become more
marked and varied from their first manifestation. Finally, neuronal loss and the clinical onset of disease
can be observed. An example of a time course of TSE disease is summarised in Figure 2.
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Figure 2. Time course of a TSE infection; ME7/C57BL. The urine TSE strain, ME7 is intracerebrally
inoculated into C57BL mice. The total incubation period in this model is approximately 24 weeks.
PrPSc and gliosis can be detected from eight weeks post inoculation. This is followed by changes in
behavioural signs (from 10 weeks), synaptic loss (from 12 weeks), neuronal loss (from 19 weeks) and
overt clinical signs can be observed from approximately 20 weeks. Data in this figure was obtained
from [62,63,67].
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At clinical stages, PrPSc is usually detected in brain regions undergoing neurodegeneration.
The accumulation and aggregation of PrPSc occurs long before detectable neurodegeneration [63,69]
and the spread of misfolded protein between distinct brain regions is thought to determine the
specific brain regions that undergo neurodegeneration (reviewed in [40,70]). These studies have led
many to conclude that the misfolding of the host protein is the initiating and causative factor of
neurodegeneration [71–73]. However, a number of findings question the direct relationship between
protein misfolding and neurodegeneration. For example, in some TSEs, misfolded PrP accumulates
in the brain in some situations unaccompanied by the other typical neuropathological changes or
any clinical signs of disease [5,74,75]. Protein accumulation in the brain in the absence of clinical
disease has also been observed in AD with accumulation of Aβ-amyloid plaques in the brains of
cognitively normal, aged individuals [15]. Thus, the relationship between misfolded proteins and
neurodegeneration is not fully established.
5. Neurodegeneration and Protein Misfolding
The accumulation of PrPSc aggregates is thought to be associated with either a toxic gain of
function or loss of normal function [76]. The prevailing hypothesis is that the protein aggregates
or seeds trigger a cascade of events leading to neurodegeneration. It has been proposed that the
formation of an initial protein assembly, referred to as a nucleation event or seed, catalyzes the
conversion of normal protein into a pathologic state. Once seeded, growth of amyloid-like structures
is typically exponential, resulting in the formation of macromolecular structures that appear as intra or
extracellular deposits used to pathologically define the disease [8,77]. Whether this seeding and spread
of the misfolded protein results in a clinical disease, however, may also depend on the host response
to the misfolded protein. Recent studies have shown the formation of PrP-amyloid in the absence of
other prion-associated pathological changes or clinical signs, indicating that seeded polymerization of
misfolded protein aggregates does not always results in neurodegeneration [5,74,75]. Moreover, recent
studies by Alibhai et al. [78] have challenged the concept that the accumulation and spread of misfolded
protein determines neurodegeneration by showing that proteins seeds alone are not pathogenic.
This raises the question of what, in addition to misfolded protein, is required for a neurodegenerative
cascade, which will be further addressed in Section 6. Glial Cells and Neurodegeneration.
In studies in which transgenic mice overexpressing human forms of amyloid precursor protein
(APP) were inoculated with brain homogenates containing human Aβ aggregate, further formation of
Aβ aggregates was evident [20]. Other disease-associated protein aggregates, such as tau aggregates,
can also experimentally induce and propagate after inoculation into transgenic mice expressing
human tau [22–24]. Similarly to TSE diseases, the inoculation of α-synuclein containing brain
extracts or aggregates into transgenic and wild type mice resulted in clinical disease and α-synuclein
deposition [79,80] or clinical disease, cell-to-cell transmission of pathologic α-synuclein and
Parkinson’s-like Lewy pathology in anatomically interconnected areas respectively [26]. In addition,
aggregation and propagation of endogenous tau were observed in wild type mice inoculated with
tau oligomers purified from the brain of an AD patient [25]. Seeding of β-amyloidosis has also been
reported in non-human primates injected intracerebrally with human or marmoset brain homogenate
containing β-amyloid [81].
Similar to evidence presented in TSEs, this spread of the misfolded protein appears to occur in
a pattern resembling neuronal connectivity [22–26,82,83]. Furthermore, peripheral administration
of disease-associated aggregates into mice also has the capability to trigger subsequent protein
aggregation in the brain [84,85]. The relevance of this recent array of data has led to the interpretation
that disease-associated misfolded proteins, such as Aβ, tau and α-synuclein, amongst others, can
transmit between cells in a prion-like mechanism (reviewed in [86–88]). It is therefore important
to understand the implications for these protein accumulations in terms of clinical disease and
transmission of disease to another host.
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6. Glial Cells and Neurodegeneration
The high levels of PrP expression in the neuronal cells of the CNS have led researchers to focus
on neuronal cells in defining mechanisms of neurodegeneration in the TSEs. PrP mRNA is found
throughout neuronal cells of the brain but with variable levels in different neuronal populations [89,90].
Evidence for a cell autonomous neurodegenerative mechanism has been provided from in vivo studies
with transgenic mice designed to express PrPC in neurons only, which were shown to be susceptible
to TSEs [91]. Conversely, using a model in which PrPC expression was removed from neurons at
a specific time point during the course of disease, the disease process appeared to be blocked [92].
The removal of neuronal PrP resulted in the reversal of TSE associated spongiform degeneration of the
brain and behavioural deficits in this model [93,94]. Other studies have demonstrated that reduction
in neuronal PrP at any point throughout the preclinical phase, right up to clinical onset, resulted in
dramatic lengthening of the pre-symptomatic period of the disease, although, in this case, all animals
ultimately developed a clinical neurodegenerative disease [95]. This extension of the pre-symptomatic
phase in this study, however, indicates that there is a wide therapeutic window prior to the onset of
clinical symptoms for possible intervention into these devastating diseases.
The expression of Prnp mRNA and PrP protein has also been described in non-neuronal cell
types in the CNS [96–98], and the accumulation of misfolded protein occurs in non-neuronal cell
types within the brain during TSE infection. Transgenic mice expressing PrP only in astrocytes
succumb to TSE infection, demonstrating that the expression of PrPC in astrocytes is sufficient to elicit
neurodegeneration and a clinical TSE disease [99]. Indeed, the astrocytic production of PrP may play a
role in sustaining the disease process in non-transgenic animals.
During the earliest stages of TSE pathogenesis within the CNS, a strong reactive glial response
is observed. Astrocytes and microglia have been implicitly linked with the disease process through
extensive pathological [66,100] and gene expression analysis [101]. Astrocytes are sensitive to changes
in homeostasis, injury to the CNS and the presence of misfolded proteins [102], and undergo a complex
response, morphologically characterised by hypertrophy of the cell body and shortening/thickening
of processes [103,104]. During TSE, it has been reported that PrPSc accumulates in astrocytes [105],
and, therefore, it could be argued that a loss of astrocyte function could be an important component
of the disease process. Astrogliosis is observed prior to functional synaptic deficits and concurrently
with the appearance of detectable PrPSc [63] suggesting astrocyte activation is occurring as a result of
misfolded protein. Alternatively, astrocyte activation may occur directly in response to degenerating
neurons or other CNS insults [106].
An activated morphological response by microglia is also observed early following neuroinvasion
or during the early stages after intracerebral inoculation. This morphological response is accompanied
by a mixed cytokine response that includes mediators of both potent inflammatory responses
e.g., IL-1B, IL6 and anti-inflammatory responses such as TGFB1 and IL10 [107,108]. Inhibition of
microglial proliferation results in increases in the TSE incubation period [109] suggesting a potential
for therapeutic intervention by modulating the microglial response to disease.
Genetic knockout (KO) models of genes involved in the innate immune response have been
shown to influence the incubation period of TSEs [110]. For example, KO of Il1r1, Ccl2, Cxcr3 and
Cd14 result in a prolonged incubation period [111–114]. KO or knock-down of Tgfb1, IL4, IL10, IL13 or
Ccr1, on the other hand, results in a shortened incubation period [111,115,116]. This data demonstrates
that altering the innate immune response in specific ways can alter pathogenesis and progression of
disease, highlighting an important role of glial cells in the disease process. However, exactly how
non-neuronal cells support the disease mechanism is not yet clear and whether their activation occurs
in response to degenerating neurons, protein deposition or other CNS insults is still a matter for debate.
Understanding the interactions between neuronal and glial cells in the disease process may prove
important in defining the mechanisms underlying neurodegeneration
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7. Protein Misfolding and Infection
The exact nature of the infectious entity in TSE has not been determined. Estimates on the size
of the most infectious PrP particle have varied [117–124] and co-factors have been suggested that are
required for the infectious process [36,125–133]. Moreover, while the TSE in general are considered
to be infectious, there is a wide range of infectious potential amongst these diseases ranging from
the contagious diseases such as Chronic Wasting Disease (CWD) and scrapie [134,135] through to
those with zoonotic potential such as Bovine Spongiform Encephalopathy (BSE) [136–138] and others
which are extremely hard to transmit such as the human forms of disease [139–142]. Results from the
National Institutes of Health series of 300 experimentally transmitted cases into non-human primates
show highest transmission rates for iatrogenic and sporadic cases and lower for familial forms of
disease [139].
There are many strains of TSE agents described by their differences in incubation period, pathology
and biochemical properties [143]. The exact definition of these strains has yet to be made, but
explanations from nucleic acid [144,145] to the conformation of PrPSc [146–149], or host-specific
factors other than PrPC have been put forward [150]. The idea for conformation of misfolded protein
defining strains has been extended to other non-prion misfolded proteins such as Aβ [151], tau [152]
and α-synuclein [153,154] and may go some way to defining different clinical phenotypes that are
observed in the associated diseases.
It has been proposed that sequence identity between PrPC in the host and PrPSc in the inoculum
is central for the efficient transmission of disease between individuals [155]. Others have suggested
conformation rather than sequence determines transmission characteristics [149,156]. However, this is
not always the case [50,157,158]. Glycosylation of host PrP has been considered to be an important
factor [58,59]. Transgenic mice expressing fully or glycosylation deficient PrP isoforms have been
exposed to TSE strains with distinct glycosylation patterns, and it has been shown that transmission of
TSE agents across species can be profoundly influenced by the glycosylation status of both PrPC and
PrPSc [56,57,159,160].
Transgenic models were further developed to assess the influence of disease-associated mutations
in the PRNP gene on the development of disease. “Knock-in” transgenic mice with a targeted
proline (P) to leucine (L) mutation in the Prnp gene (101LL) were generated to model a familial
TSE, Gerstmann-Sträussler-Scheinker (GSS) P102L disease [51]. The 101LL mice do not develop any
spontaneous TSE but proved to be highly susceptible to several TSE strains. When 101LL mice were
inoculated with brain extracts from patients with “typical” GSS P102L (with widespread spongiform
degeneration, diffuse and amyloid PrP deposits), they developed neurological signs and replicated
high titers of infectivity in the brain. However, unexpectedly, no PrPSc was observed in the brain of
these mice by Western blot analysis [161]. Similar cases of TSE disease in the absence of detectable
PrPSc was reported by Lasmezas et al. with the transmission of BSE to mice [162] and in transmission
of atypical/Nor98 scrapie from peripheral tissues with no detectable PrPSc [163]. Recent studies using
highly sensitive detection systems (such as PMCA) for the identification of small amounts of PrPSc
showed prion infectivity in peripheral tissues of terminally diseased BSE field cases in the absence of
detectable PrPSc [164]. The importance of these studies has been to question the relationship between
PrPSc and infectivity, and, indeed, these studies lead to the suggestion that both PK resistant and PK
sensitive forms of the prion protein had infectious potential [165–167].
The relationship between misfolded PrP and infection has been further confounded by the
inoculation of partially purified PrPSc from a patient with atypical GSS P102L into 101LL mice, which
resulted in the accumulation of large multicentric amyloid plaques in restricted areas of the brain but
no clinical disease or spongiform degeneration of the brain. Subsequent sub-passages of the brain
material from these mice into 101LL mice showed the presence of PrP amyloid without any clinical
signs of disease (Figure 3) [5]. These studies demonstrate that infectivity may not always be directly
related to PrP pathogenicity, and, moreover, protein accumulation in the CNS does not always lead to
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a clinical disease [5,74,168]. This raises the question of which PrPSc isoform(s) are neurotoxic, which
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intra-cerebral inoculation into mice and non-human primates [20,22–27,81]. The misfolded proteins are 
proposed to transmit between cells in a prion-like mechanism; this also infers that they may have the 
potential to be infectious i.e., transmit between individuals. Murine transmission studies involving 
peripheral inoculations of misfolded protein have provided evidence that peripheral challenge with 
Aβ and tau can cause protein aggregation in the brain [84,85]. These studies used overexpression mouse 
models, which have the potential to accelerate disease progression, develop spontaneous disease and 
the expression of protein can vary throughout the body, making interpretation of the studies difficult. 
Jaunmuktane et al. observed the presence of Aβ in individuals who had received human pituitary-
derived growth hormone prompting consideration that iatrogenic routes of transmission may be 
relevant to Aβ and other non-prion misfolded proteins as well as TSEs [28]. However, there is no 
epidemiological evidence to support this having occurred [30]. Understanding the association between 
a misfolded protein and neurotoxicity or infectivity will aid us in determining whether all protein 
misfolding diseases represent a risk to public health. 
8. Conclusions 
In view of the central role of the host-encoded proteins such as PrP in TSEs, amyloid precursor 
protein (APP) in AD and microtubule associated protein (tau) in AD, PD and tauopathies, these 
neurodegenerative diseases are grouped together as protein misfolding diseases [20,21,29,170–178]. 
Increasing numbers of publications describe the spread of AD, PD and other diseases by what is called 
a “prion-like” mechanism. The data focus on the cell-to-cell spread of misfolded protein aggregates as 
a general pathogenic phenomenon. Most neurodegenerative disorders (e.g., AD, PD) have previously 
Figure 3. Transmission of atypical GSS P102L into 101LL mice. Intracerebral inoculation of partially
purified PrPSc (brain homogenate) from a patient with atypical GSS P102L into 101LL transgenic mice
resulted in multicentric PrP-positive plaques in the corpus callosum and periventricular zone of 101LL
mice at >600 days post inoculation (dpi). Two subsequent subpassages using infected 101LL mouse
brain homogenate also showed multicentric PrP-positive plaques, again at 600 dpi. No clinical signs of
prion disease or vacuolar pathology were observed in any mice despite the presence of PrP-amyloid
plaques. PrP-amyloid stained with anti PrP Mab 6H4 [169]. Arrows indicate PrP amyloid plaques.
As discussed in Section 5. Neurodegeneration and Protein Misfolding, numerous studies have
provided evidence that non-prion misfolded protein can induce aggregate formation following
intra-cerebral inoculation into mice and non-human primates [20,22–27,81]. The misfolded proteins
are proposed to transmit between cells in a prion-like mechanism; this also infers that they may have
the potential to be infectious i.e., transmit between individuals. Murine transmission studies involving
peripheral inoculations of misfolded protein have provided evidence that peripheral challenge with Aβ
and tau can cause protein aggregation in the brain [84,85]. These studies used overexpression mouse
models, which have the potential to accelerate disease progression, develop spontaneous disease
and the expression of protein can vary throughout the body, making interpretation of the studies
difficult. Jaunmuktane et al. observed the presence of Aβ in individuals who had received human
pituitary-derived growth hormone prompting consideration that iatrogenic routes of transmission
may be relevant to Aβ and other non-prion misfolded proteins as well as TSEs [28]. However, there
is no epidemiological evidence to support this having occurred [30]. Understanding the association
between a misfolded protein and neurotoxicity or infectivity will aid us in determining whether all
protein misfolding diseases represent a risk to public health.
8. Conclusions
In view of the central role of the host-encoded proteins such as PrP in TSEs, amyloid precursor
protein (APP) in AD and microtubule associated protein (tau) in AD, PD and tauopathies, these
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neurodegenerative diseases are grouped together as protein misfolding diseases [20,21,29,170–178].
Increasing numbers of publications describe the spread of AD, PD and other diseases by what is called
a “prion-like” mechanism. The data focus on the cell-to-cell spread of misfolded protein aggregates as
a general pathogenic phenomenon. Most neurodegenerative disorders (e.g., AD, PD) have previously
not been considered to be infectious diseases. Indeed, there is no epidemiological data to suggest
that they are infectious [30]. It is important, therefore, to understand when a misfolded protein has
the potential to lead to clinical disease and to be transmitted between individuals via natural routes
of transmission, which should be considered a different scenario from cell-to-cell spread within an
individual. Thus, determining the difference between protein aggregates associated with neurotoxicity
and infectivity and those aggregates that are benign is essential to determine when diseases associated
with protein misfolding are threats to individuals and to public health. The TSE systems have given
some insights and invaluable tools to study these disease mechanisms; in particular, early events
in disease pathogenesis can be elucidated. It has been shown that both agent and host define the
infectious nature of these diseases. Moreover, glial and neuronal cells are important to the disease
process. While these studies are pointing to new avenues for therapeutic intervention, we are still
some way from providing a clear understanding of these complex disease processes. However, by
using a concerted approach to the family of prion-like diseases rather than considering each disease
in isolation, we might provide more rapid progress to understanding the underlying mechanisms
of the disease process and develop novel intervention strategies applicable to all forms of protein
misfolding diseases.
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